USE OF VEGF-B FOR TREATING DISEASES INVOLVING NEOANGIOGENESIS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Feb 28, 2019
app pub date -
Aug 31, 2018
filing date -
Aug 31, 2017
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The invention discloses a method for treating a disease involving neoangiogenesis, including administering VEGF-B to a subject; and, a pharmaceutical composition containing VEGF-B protein, VEGF-B expressing plasmids, VEGF-B expressing viruses and/or VEGF-B expressing cells as active ingredients for treating a disease involving neoangiogenesis. The VEGF-B of the invention is able to bind to FGF2 receptors FGFR1 and FGFR2, induces the formation of FGFR1/VEGFR1 or FGFR2/VEGFR1 complex, inhibits the functions of FGFR1 and FGFR2, up-regulates Spry4 expression, and inhibits FGF2 from activating Erk, thus inhibiting neoangiogenesis.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully